Drug Discovery World
OCTOBER 13, 2022
The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery.
Drug Discovery World
DECEMBER 13, 2023
This article is sponsored by Fortis Life Sciences. Fortis Life Sciences offers custom antibody discovery and manufacturing services for antibodies and single-domain antibodies, supporting the drug discovery market. Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 22, 2022
Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry?
Drug Discovery World
APRIL 3, 2023
As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. What advice would you offer to similar start-ups? AT: Integral to Aptamer Group’s offering is an in-depth understanding of molecular science.
XTalks
OCTOBER 1, 2020
A life-changing moment came for Dr. Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. The journey first starts with the decision to make the switch. Key Moments.
Drug Discovery World
FEBRUARY 15, 2023
Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers. This continues to be the standard of care.
Drug Discovery World
JULY 18, 2023
Incorporating in vivo pooled CRISPR screens has allowed for the interrogation of thousands of genetic perturbations in cells, leading to the determination of the involvement of molecules (PTPN2, ADAR1, or DHX37) in immune checkpoint inhibitor (ICI) responsiveness and T cell activation.
Expert insights. Personalized for you.
52 
Let's personalize your content